Surufatinib for neuroendocrine tumors in everyday clinical care
Observes how safe surufatinib is, and how well it works, in adults with neuroendocrine tumors.
Plain-language title generated from the registry record
Registry title: Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors
Key facts
- Where
- Xiamen, ChinaSee the site
Where in China
- The First Affiliated hospital of Xiamen UniversityXiamen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yefeng
- Trial code
- NCT07780539
- Record updated
- 21 August 2026
- Original description
Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs). This real-world study aims to evaluate the clinical efficacy and safety of surufatinib in patients with NETs, providing additional real-world evidence to support clinical application, guide novel therapeutic strategies, and ultimately improve patient outcomes.Read full original descriptionShow less
Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors
Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs). This real-world study aims to evaluate the clinical efficacy and safety of surufatinib in patients with NETs, providing additional real-world evidence to support clinical application, guide novel therapeutic strategies, and ultimately improve patient outcomes.
Inclusion: Patients with pathologically or cytologically confirmed neuroendocrine tumors; At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; Life expectancy ≥ 12 weeks; Adequate organ and bone marrow function.
Exclusion: Participation in other drug clinical trials with investigational drug treatment within the past 4 weeks; History of other malignancies within the past 5 years, except for curatively resected basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ; Patients with contraindications to surufatinib (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, within 30 days after major surgery, severe hepatic or renal impairment, etc.); Presence of any disease or condition that affects drug absorption, or inability to take surufatinib orally; Any condition deemed by the investigator as unsuitable for study drug treatment.